17.50
price up icon0.06%   0.01
after-market Dopo l'orario di chiusura: 17.95 0.45 +2.57%
loading
Precedente Chiudi:
$17.49
Aprire:
$17.46
Volume 24 ore:
110.85K
Relative Volume:
6.04
Capitalizzazione di mercato:
$233.44M
Reddito:
-
Utile/perdita netta:
-
Rapporto P/E:
-
EPS:
-
Flusso di cassa netto:
-
1 W Prestazione:
+1.86%
1M Prestazione:
+0.00%
6M Prestazione:
+0.00%
1 anno Prestazione:
+0.00%
Intervallo 1D:
Value
$16.50
$17.76
Intervallo di 1 settimana:
Value
$16.50
$17.93
Portata 52W:
Value
$16.50
$19.40

Onkure Therapeutics Inc Stock (OKUR) Company Profile

Name
Nome
Onkure Therapeutics Inc
Name
Telefono
(858) 283-0280
Name
Indirizzo
18575 JAMBOREE ROAD, IRVINE
Name
Dipendente
0
Name
Cinguettio
Name
Prossima data di guadagno
2024-11-11
Name
Ultimi documenti SEC
Name
OKUR's Discussions on Twitter

Onkure Therapeutics Inc Borsa (OKUR) Ultime notizie

pulisher
Oct 25, 2024

VTv, OnKure Terminate Cellular Drug Licensing Agreement - MarketWatch

Oct 25, 2024
pulisher
Oct 25, 2024

vTv Therapeutics ends key license agreement with OnKure - Investing.com

Oct 25, 2024
pulisher
Oct 25, 2024

vTv Therapeutics ends key license agreement with OnKure By Investing.com - Investing.com UK

Oct 25, 2024
pulisher
Oct 24, 2024

OnKure: Looking To Alter PI3K Inhibitor Targeting In Breast Cancer And Beyond (OKUR) - Seeking Alpha

Oct 24, 2024
pulisher
Oct 21, 2024

Q3 Earnings Forecast for OKUR Issued By HC Wainwright - MarketBeat

Oct 21, 2024
pulisher
Oct 19, 2024

Analysts Offer Predictions for OKUR Q1 Earnings - Defense World

Oct 19, 2024
pulisher
Oct 18, 2024

What is HC Wainwright's Estimate for OKUR Q1 Earnings? - MarketBeat

Oct 18, 2024
pulisher
Oct 17, 2024

HC Wainwright Reiterates Buy Rating for OnKure Therapeutics (NASDAQ:OKUR) - MarketBeat

Oct 17, 2024
pulisher
Oct 14, 2024

OnKure Therapeutics (OKUR) Stock Rebounds In Extended Session - Stocks Telegraph

Oct 14, 2024
pulisher
Oct 11, 2024

OnKure started at outperform by Oppenheimer, OKI-219 potential cited - MSN

Oct 11, 2024
pulisher
Oct 11, 2024

OnKure shares initiated with Outperform rating on drug potential - Investing.com India

Oct 11, 2024
pulisher
Oct 10, 2024

Recently Listed Cancer Firm OnKure's Innovative Approach to Breast Cancer Treatment Sparks Analyst Enthusiasm - Benzinga

Oct 10, 2024
pulisher
Oct 10, 2024

OnKure shares initiated with Outperform rating on drug potential By Investing.com - Investing.com Canada

Oct 10, 2024
pulisher
Oct 10, 2024

This Builders FirstSource Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday - Benzinga

Oct 10, 2024
pulisher
Oct 08, 2024

Reneo Pharmaceuticals Completes Merger and Name Change to OnKure Therapeutics, Inc. - MarketBeat

Oct 08, 2024
pulisher
Oct 08, 2024

Newley merged OnKure raises $65 million - The Pharma Letter

Oct 08, 2024
pulisher
Oct 07, 2024

Boulder’s OnKure goes public with merger; key drug trial underway - Boulder Daily Camera

Oct 07, 2024
pulisher
Oct 07, 2024

OnKure and Reneo Pharmaceuticals complete merger - Pharmaceutical Technology

Oct 07, 2024
pulisher
Oct 05, 2024

Reneo Pharmaceuticals stockholders approval merger with OnKure - TipRanks

Oct 05, 2024
pulisher
Oct 04, 2024

OnKure Announces Closing of Merger with Reneo Pharmaceuticals and Concurrent Private Placement of $65 Million - StockTitan

Oct 04, 2024
pulisher
Oct 04, 2024

Reneo stockholders approve merger with OnKure - MSN

Oct 04, 2024
pulisher
Oct 02, 2024

Reneo Pharmaceuticals Announces Stockholder Approval of Merger with OnKure | RPHM Stock News - StockTitan

Oct 02, 2024
pulisher
Sep 22, 2024

This Stock Is Crushing Nvidia's Performance This Year: Is It Too Late to Buy? - AOL

Sep 22, 2024
pulisher
Sep 17, 2024

Here's Why Everyone's Talking About Summit Therapeutics - AOL

Sep 17, 2024
pulisher
Sep 10, 2024

Oppenheimer sees competition risk as Relay Therapeutics stock stumbles on trial results - Investing.com

Sep 10, 2024
pulisher
Aug 13, 2024

Reneo Pharmaceuticals Reports Second Quarter 2024 Financial Results - Yahoo Finance

Aug 13, 2024
pulisher
Jun 24, 2024

STOCKHOLDER INVESTIGATION: The M&A Class Action Firm Investigates Merger of Reneo Pharmaceuticals, Inc.RPHM - PR Newswire

Jun 24, 2024
pulisher
May 28, 2024

Reneo Set to Close After Test Failure - Orange County Business Journal

May 28, 2024
pulisher
May 17, 2024

Public Equity Report: Erasca reboots, Telix plans NASDAQ listing - BioCentury

May 17, 2024
pulisher
May 15, 2024

Wilson Sonsini Advises Reneo Pharmaceuticals on IP Matters Related to OnKure Merger - Wilson Sonsini

May 15, 2024
pulisher
May 13, 2024

Reneo Pharmaceuticals and OnKure Announce Proposed Merger - GlobeNewswire

May 13, 2024
pulisher
Apr 16, 2024

Seven biotech companies climbing their way up in Colorado - Labiotech.eu

Apr 16, 2024
pulisher
Jan 08, 2024

HDAC Inhibitor Clinical Trial Pipeline Appears Robust With - GlobeNewswire

Jan 08, 2024
pulisher
Dec 20, 2023

Fierce Biotech Fundraising Tracker '23: Carmot spinoff Kimia raises $55M; Lassen fuels for fibro-inflammatory mission - Fierce Biotech

Dec 20, 2023
pulisher
May 26, 2023

The Week’s 10 Biggest Funding Rounds: Anthropic Generates Another Huge Round, Biotech Has Big Week - Crunchbase News

May 26, 2023
pulisher
May 23, 2023

OnKure Therapeutics Announces $54 Million Series C Financing - GlobeNewswire

May 23, 2023
pulisher
Feb 28, 2023

2023 Destination Startup® drives investment in intermountain west university innovations - University of Colorado Boulder

Feb 28, 2023
pulisher
Feb 09, 2022

Biogen’s Friedl-Naderer joins Vir as CBO - BioCentury

Feb 09, 2022
pulisher
May 19, 2021

RPHMReneo Pharmaceuticals, Inc. Latest Stock News & Market Updates - StockTitan

May 19, 2021
pulisher
Mar 04, 2021

OnKure, Inc. Raises $55 Million Series B Financing - Business Wire

Mar 04, 2021
pulisher
Nov 07, 2019

Tyler D. Baguley - Wilson Sonsini

Nov 07, 2019
pulisher
Jun 24, 2019

Immunotherapy and HDAC inhibition are anti-cancer besties - University of Colorado Anschutz Medical Campus

Jun 24, 2019
pulisher
Jun 17, 2019

OnKure and CU Cancer Center announce first patient enrolled in clinical trial of OKI-179, a potent and selective HDAC inhibitor - University of Colorado Anschutz Medical Campus

Jun 17, 2019

Onkure Therapeutics Inc Azioni (OKUR) Dati Finanziari

Non sono disponibili dati finanziari per Onkure Therapeutics Inc (OKUR). Controlla altri titoli per ulteriori informazioni.

Reddito

loading

Reddito netto

loading

Flusso di cassa

loading

EPS

loading
$22.32
price down icon 1.11%
$74.12
price up icon 0.26%
$373.97
price up icon 3.48%
$54.36
price down icon 0.66%
$202.64
price down icon 1.63%
$113.10
price down icon 0.74%
Capitalizzazione:     |  Volume (24 ore):